New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program
A common tool for detecting mild cognitive impairment (MCI) is the Montreal Cognitive Assessment (MoCA). An extension of the standard MoCA testing – MoCA-Memory Index Score (MoCA-MIS; Memory Index, MI) – allows a deeper study of the mechanisms of MCI formation. We consider the drug Prospecta as an e...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2023-02-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1955 |
| _version_ | 1797876322023768064 |
|---|---|
| author | E. Y. Solovieva P. R. Kamchatnov L. B. Novikova O. A. Kicherova N. M. Khasanova |
| author_facet | E. Y. Solovieva P. R. Kamchatnov L. B. Novikova O. A. Kicherova N. M. Khasanova |
| author_sort | E. Y. Solovieva |
| collection | DOAJ |
| description | A common tool for detecting mild cognitive impairment (MCI) is the Montreal Cognitive Assessment (MoCA). An extension of the standard MoCA testing – MoCA-Memory Index Score (MoCA-MIS; Memory Index, MI) – allows a deeper study of the mechanisms of MCI formation. We consider the drug Prospecta as an effective measure to prevent the progression of MCI.Objective: to study the efficacy and safety of Prospecta in the treatment of MCI in patients with cerebrovascular disease (CVD) in real clinical practice.Material and methods. The observational program PRIORITET included 192 patients of both sexes aged 40 to 74 years inclusive (mean age 63.6±8.8 years) with MCI and CVD, they were prescribed Prospecta, two tablets twice a day during 24 weeks. The presence of MCI was confirmed by testing on the MoCA scale; MI was assessed additionally`. At the end of treatment, the condition of patients was assessed using the Overall Clinical Impression Scale and the safety of the therapy.Results. The change in the mean score on the MoCA scale after 24 weeks of therapy with Prospecta was 5.3 (p<0.0001). The proportion of patients who responded positively to treatment with Prospecta and after 24 weeks of treatment restored their cognitive functions to normal (MoCA >26 points), reached 48.9%. Additionally, patients were divided into groups depending on the results of testing on the MoCA scale and MI. During therapy with Prospecta, the number of patients in the MIS <7 and MoCA <20 group decreased by 19 times, in the MIS <7 or MoCA <20 group – by 4.8 times. There were 16 adverse events, 75% of which were mild. In 62.5% of adverse events, there was no connection with taking Prospecta.Conclusion. Prospecta is an effective and safe treatment for patients with MCI and CVD. |
| first_indexed | 2024-04-10T02:00:16Z |
| format | Article |
| id | doaj.art-e173111ac0bc4750a6871d7afd4c87ff |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2024-04-10T02:00:16Z |
| publishDate | 2023-02-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-e173111ac0bc4750a6871d7afd4c87ff2023-03-13T08:42:23ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422023-02-01151657010.14412/2074-2711-2023-1-65-701343New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation ProgramE. Y. Solovieva0P. R. Kamchatnov1L. B. Novikova2O. A. Kicherova3N. M. Khasanova4Pirogov Russian National Research Medical University, Ministry of Health of RussiaPirogov Russian National Research Medical University, Ministry of Health of RussiaBashkir State Medical University, Ministry of Health of RussiaTyumen State Medical University, Ministry of Health of RussiaNorthern State Medical University, Ministry of Health of RussiaA common tool for detecting mild cognitive impairment (MCI) is the Montreal Cognitive Assessment (MoCA). An extension of the standard MoCA testing – MoCA-Memory Index Score (MoCA-MIS; Memory Index, MI) – allows a deeper study of the mechanisms of MCI formation. We consider the drug Prospecta as an effective measure to prevent the progression of MCI.Objective: to study the efficacy and safety of Prospecta in the treatment of MCI in patients with cerebrovascular disease (CVD) in real clinical practice.Material and methods. The observational program PRIORITET included 192 patients of both sexes aged 40 to 74 years inclusive (mean age 63.6±8.8 years) with MCI and CVD, they were prescribed Prospecta, two tablets twice a day during 24 weeks. The presence of MCI was confirmed by testing on the MoCA scale; MI was assessed additionally`. At the end of treatment, the condition of patients was assessed using the Overall Clinical Impression Scale and the safety of the therapy.Results. The change in the mean score on the MoCA scale after 24 weeks of therapy with Prospecta was 5.3 (p<0.0001). The proportion of patients who responded positively to treatment with Prospecta and after 24 weeks of treatment restored their cognitive functions to normal (MoCA >26 points), reached 48.9%. Additionally, patients were divided into groups depending on the results of testing on the MoCA scale and MI. During therapy with Prospecta, the number of patients in the MIS <7 and MoCA <20 group decreased by 19 times, in the MIS <7 or MoCA <20 group – by 4.8 times. There were 16 adverse events, 75% of which were mild. In 62.5% of adverse events, there was no connection with taking Prospecta.Conclusion. Prospecta is an effective and safe treatment for patients with MCI and CVD.https://nnp.ima-press.net/nnp/article/view/1955cognitive impairmentcerebrovascular diseasesreal clinical practicepharmacotherapyprospecta |
| spellingShingle | E. Y. Solovieva P. R. Kamchatnov L. B. Novikova O. A. Kicherova N. M. Khasanova New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program Неврология, нейропсихиатрия, психосоматика cognitive impairment cerebrovascular diseases real clinical practice pharmacotherapy prospecta |
| title | New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program |
| title_full | New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program |
| title_fullStr | New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program |
| title_full_unstemmed | New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program |
| title_short | New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program |
| title_sort | new possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease results of the prioritet observation program |
| topic | cognitive impairment cerebrovascular diseases real clinical practice pharmacotherapy prospecta |
| url | https://nnp.ima-press.net/nnp/article/view/1955 |
| work_keys_str_mv | AT eysolovieva newpossibilitiesforthetreatmentofmildcognitiveimpairmentandpreventionofdementiainpatientswithcerebrovasculardiseaseresultsoftheprioritetobservationprogram AT prkamchatnov newpossibilitiesforthetreatmentofmildcognitiveimpairmentandpreventionofdementiainpatientswithcerebrovasculardiseaseresultsoftheprioritetobservationprogram AT lbnovikova newpossibilitiesforthetreatmentofmildcognitiveimpairmentandpreventionofdementiainpatientswithcerebrovasculardiseaseresultsoftheprioritetobservationprogram AT oakicherova newpossibilitiesforthetreatmentofmildcognitiveimpairmentandpreventionofdementiainpatientswithcerebrovasculardiseaseresultsoftheprioritetobservationprogram AT nmkhasanova newpossibilitiesforthetreatmentofmildcognitiveimpairmentandpreventionofdementiainpatientswithcerebrovasculardiseaseresultsoftheprioritetobservationprogram |